Literature DB >> 27448808

Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.

J Ward1, C Wood2, K Rouch3, D Pienkowski1, H H Malluche4,5.   

Abstract

UNLABELLED: Apparent modulus and failure stress of trabecular bone structure from 45 women with osteoporosis treated with bisphosphonates for varying durations were studied using finite element analyses and statistical modeling. Following adjustments for patient age and bone volume, increasing bisphosphonate treatment duration for up to 7.3 years was associated with treatment-time-dependent increases in bone apparent modulus and failure stress. Treatment durations exceeding 7.3 years were associated with time-dependent decreases in apparent modulus and failure stress from the peak values observed.
INTRODUCTION: The purpose of this study was to clarify the relationship between bisphosphonate (BP) treatment duration and human bone quality. This study quantified changes in the apparent modulus and failure stress of trabecular bone biopsied from patients with osteoporosis who were treated with BPs for widely varying durations.
METHODS: Forty-five iliac crest bone samples were obtained from women with osteoporosis who were continuously treated with oral BPs for varying periods of up to 16 years. Micro-CT imaging was used to develop three-dimensional virtual models of the trabecular bone from these samples. Apparent modulus and failure stress of these virtual models were determined using finite element analyses (FEA). Polynomial regression and cubic splines, adjusted for relevant (age and BV/TV) covariates, were used to statistically model the data and quantify the relationships between BP treatment duration and apparent modulus or failure stress.
RESULTS: Second-order polynomial models were needed to relate apparent modulus or failure stress to BP treatment duration. These models showed that these bone quality parameters (a) increased with increasing BP treatment duration up to approximately 7.3 years, (b) reached a maximum at this (~7.3 years) time, and then (c) declined with BP treatment durations exceeding ~7.3 years. A similar result was obtained by modeling with cubic splines.
CONCLUSIONS: Changes in FEA-derived apparent stiffness and failure stress are attributable to changes in trabecular bone structure, which in turn are related to the duration of BP treatment. These relationships are evident even after adjustments are made in the statistical models for changes in age and BV/TV. According to these models, increases in trabecular bone apparent stiffness and failure stress linked to BPs cease and appear to reverse after approximately 7.3 years of treatment. Conclusions regarding optimal BP therapy duration await study of additional bone quality parameters.

Entities:  

Keywords:  Antiresorptives; Biomechanics; Bone quality; Finite element analyses; Osteoporosis

Mesh:

Substances:

Year:  2016        PMID: 27448808     DOI: 10.1007/s00198-016-3661-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  49 in total

1.  Accuracy of cancellous bone volume fraction measured by micro-CT scanning.

Authors:  M Ding; A Odgaard; I Hvid
Journal:  J Biomech       Date:  1999-03       Impact factor: 2.712

2.  Intrinsic material properties of trabecular bone by nanoindentation testing of biopsies taken from healthy women before and after menopause.

Authors:  Benjamin J Polly; Philip A Yuya; Mohammed P Akhter; Robert R Recker; Joseph A Turner
Journal:  Calcif Tissue Int       Date:  2012-02-21       Impact factor: 4.333

3.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

4.  A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models.

Authors:  B van Rietbergen; H Weinans; R Huiskes; A Odgaard
Journal:  J Biomech       Date:  1995-01       Impact factor: 2.712

Review 5.  Safety of bisphosphonates in the treatment of osteoporosis.

Authors:  Robert R Recker; E Michael Lewiecki; Paul D Miller; James Reiffel
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

Review 6.  Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Authors:  John P Bilezikian
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

7.  Finite element analysis for prediction of bone strength.

Authors:  Philippe K Zysset; Enrico Dall'ara; Peter Varga; Dieter H Pahr
Journal:  Bonekey Rep       Date:  2013-08-07

8.  Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.

Authors:  Babul Borah; Thomas E Dufresne; Paula A Chmielewski; Gary J Gross; Marla C Prenger; Roger J Phipps
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

9.  Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

Authors:  J S Day; M Ding; P Bednarz; J C van der Linden; T Mashiba; T Hirano; C C Johnston; D B Burr; I Hvid; D R Sumner; H Weinans
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

Review 10.  Bisphosphonates: mechanism of action and role in clinical practice.

Authors:  Matthew T Drake; Bart L Clarke; Suneep Khosla
Journal:  Mayo Clin Proc       Date:  2008-09       Impact factor: 7.616

View more
  10 in total

1.  The use of finite element analysis to estimate the changing strength of bone following treatment for osteoporosis.

Authors:  D B Burr
Journal:  Osteoporos Int       Date:  2016-07-22       Impact factor: 4.507

Review 2.  Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties.

Authors:  Matthew R Allen
Journal:  Curr Osteoporos Rep       Date:  2018-04       Impact factor: 5.096

Review 3.  Osteoporosis in patients with diabetes after kidney transplantation.

Authors:  Elvira O Gosmanova; Aidar R Gosmanov
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

4.  Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years.

Authors:  D Pienkowski; C L Wood; H H Malluche
Journal:  Osteoporos Int       Date:  2018-11-28       Impact factor: 4.507

5.  Prediction of incident vertebral fracture using CT-based finite element analysis.

Authors:  B T Allaire; D Lu; F Johannesdottir; D Kopperdahl; T M Keaveny; M Jarraya; A Guermazi; M A Bredella; E J Samelson; D P Kiel; D E Anderson; S Demissie; M L Bouxsein
Journal:  Osteoporos Int       Date:  2018-10-10       Impact factor: 4.507

6.  Predicting Vertebral Bone Strength Using Finite Element Analysis for Opportunistic Osteoporosis Screening in Routine Multidetector Computed Tomography Scans-A Feasibility Study.

Authors:  Nithin Manohar Rayudu; Michael Dieckmeyer; Maximilian T Löffler; Peter B Noël; Jan S Kirschke; Thomas Baum; Karupppasamy Subburaj
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-19       Impact factor: 5.555

7.  Influence of different fixation modes on biomechanical conduction of 3D printed prostheses for treating critical diaphyseal defects of lower limbs: A finite element study.

Authors:  Bingchuan Liu; Yang Lv; Xingcai Li; Zhongjun Liu; Yufeng Zheng; Peng Wen; Ning Liu; Yaping Huo; Fang Zhou; Yun Tian
Journal:  Front Surg       Date:  2022-08-24

8.  Long-term bisphosphonate treatment coupled with ovariectomy in mice provokes deleterious effects on femoral neck fracture pattern and modifies tibial shape.

Authors:  Samuel Monzem; Rafael Y Ballester; Behzad Javaheri; Blandine Poulet; Dábila A Sônego; Andrew A Pitsillides; Roberto L Souza
Journal:  Bone Jt Open       Date:  2020-09-01

9.  Mechanical metric for skeletal biomechanics derived from spectral analysis of stiffness matrix.

Authors:  Petr Henyš; Michal Kuchař; Petr Hájek; Niels Hammer
Journal:  Sci Rep       Date:  2021-08-03       Impact factor: 4.379

Review 10.  Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II.

Authors:  Kamyar Asadipooya; Mohamed Abdalbary; Yahya Ahmad; Elijah Kakani; Marie-Claude Monier-Faugere; Amr El-Husseini
Journal:  Kidney Dis (Basel)       Date:  2021-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.